Business Context and Reporting Period
Company: Oxygen Biotherapeutics, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Oxygen Biotherapeutics, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 31, 2010
Business Overview: A development-stage biotechnology company focused on oxygen delivery to tissue. Key product candidates include Oxycyte (an intravenous oxygen carrier for traumatic brain injury), Dermacyte (topical cosmetic products), and Wundecyte (wound-healing gel). The company has no approved drug products for sale and relies on financing to fund operations.
Key Financial Metrics
| Metric | Six Months Ended Oct 31, 2010 | Six Months Ended Oct 31, 2009 |
|---|---|---|
| Revenue | $6,561 | $42,981 |
| Net Loss | $(5,054,236) | $(4,985,890) |
| Net Loss Per Share (Basic & Diluted) | $(0.22) | $(0.28) |
| Cash and Cash Equivalents (Oct 31, 2010) | $837,167 | N/A |
| Working Capital (Oct 31, 2010) | $146,172 | $785,485 (Apr 30, 2010) |
| Accumulated Deficit (Oct 31, 2010) | $(86,521,814) | $(81,467,578) (Apr 30, 2010) |
| Net Cash Used in Operating Activities | $(4,389,796) | $(2,832,725) |
| Net Cash Provided by Financing Activities | $4,851,559 | $1,488,815 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped significantly to $6,561 for the six months ended Oct 31, 2010, compared to $42,981 in the prior year period, reflecting the early commercial stage of Dermacyte.
- Operating Expenses:
- Research & Development (R&D): Increased 82% to $1.72 million, driven by Phase II-b clinical trial costs for Oxycyte and increased payroll.
- Selling, General & Administrative (SG&A): Decreased 14% to $3.39 million, primarily due to reduced stock-based compensation and consulting fees, partially offset by marketing costs for Dermacyte.
- Liquidity Position: Working capital decreased from $785,485 (April 30, 2010) to $146,172 (October 31, 2010). Cash on hand increased from $632,706 to $837,167 due to financing activities.
- Financing Activity: The company raised approximately $4.4 million in net proceeds from a registered direct offering in May 2010 and received $1 million under a Securities Purchase Agreement with Vatea Fund.
Outlook, Risks, and Management Commentary
- Going Concern: The filing includes a "Going Concern" warning. The company has an accumulated deficit of $86.5 million and requires substantial additional capital to complete clinical trials. There is no assurance that funding will be available.
- Cash Runway: Management believes current cash and recent financing ($600,000 note issued Nov 2010) are sufficient to fund operations through December 31, 2010.
- Product Development:
- Oxycyte: Phase II-b clinical trials for traumatic brain injury are underway in Switzerland, Israel, and India. FDA clinical hold remains in effect for the US protocol.
- Dermacyte: Commercial sales of the cosmetic line began in April 2010.
- Wundecyte: Preclinical testing for wound-healing gel and oxygen-generating bandage is ongoing.
- Subsequent Events: On October 12, 2010, the company entered a Note Purchase Agreement to sell up to $5 million in senior unsecured promissory notes to Vatea Fund, with a $3 million final payment premium due at maturity (Oct 2013). A $600,000 note was issued in November 2010.
- Risks: Key risks include the inability to raise additional capital, delays in clinical trials, regulatory hurdles (FDA), and intense competition in the cosmetic and biotech sectors.
Investor Verification Checklist
- Capital Adequacy: Verify the status of the $5 million Note Purchase Agreement with Vatea Fund and the likelihood of closing the remaining balance before December 31, 2010.
- Clinical Trial Progress: Confirm enrollment rates and safety data for the Oxycyte Phase II-b trials in Switzerland, Israel, and India, and the status of the FDA clinical hold.
- Revenue Sustainability: Assess the commercial viability and sales trajectory of the Dermacyte cosmetic line, which currently generates minimal revenue.
- Dilution Risk: Review the terms of outstanding warrants (4.2 million) and options (582,899) and the potential impact of future equity issuances on shareholder value.
- Debt Obligations: Analyze the impact of the $3 million final payment premium on the new notes, which will be accreted as interest expense.